4.7 Article

Diabetes and Cancer A consensus report

Journal

DIABETES CARE
Volume 33, Issue 7, Pages 1674-1685

Publisher

AMER DIABETES ASSOC
DOI: 10.2337/dc10-0666

Keywords

-

Funding

  1. Amylin Pharmaceuticals, Inc.
  2. Lilly USA
  3. Merck Company, Inc.
  4. Novo Nordisk A/S
  5. Sanofi-aventis Groupe
  6. Amylin
  7. Bayer Diabetes Care
  8. Eli Lilly
  9. Mannkind
  10. Medtronic
  11. National Institutes of Health (NIH)
  12. Novo Nordisk
  13. ResMed
  14. Life Scan
  15. American Diabetes Association

Ask authors/readers for more resources

Epidemiologic evidence suggests that cancer incidence is associated with diabetes as well as certain diabetes risk factors and diabetes treatments. This consensus statement of experts assembled jointly by the American Diabetes Association and the American Cancer Society reviews the state of science concerning 1) the association between diabetes and cancer incidence or prognosis, 2) risk factors common to both diabetes and cancer, 3) possible biologic links between diabetes and cancer risk, and 4) whether diabetes treatments influence risk of cancer or cancer prognosis. In addition, key unanswered questions for future research are posed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available